Novartis Financial Results - Q1 2026
Novartis announces the company’s financial results for the first quarter of 2026.
Novartis to establish Denton, Texas, radioligand therapy site
We announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas, our fifth in the US.
Discover our medicines
See how our innovative medicines are addressing society's greatest health challenges.
Commitment to patients
From research and development to expanding access, uncover our commitment to improving people's lives.
Inspired by purpose
Learn about our people and culture, and how we're driven by our mission to reimagine medicine.
Latest News
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
